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Abstract  
Laryngeal squamous cell carcinoma (LSCC) belongs to the heterogeneous group of 
head and neck cancers. In the etiology of LSCC, beside important environmental factors,  
genetic and epigenetic factors play a role in defining an individual's susceptibility to LSCC. 
One such epigenetic factor is DNA hypomethylation, which due to the large heterogeneity of 
the tissue, and invasiveness of the methods used, is often evaluated in easily available tissue, 
such as peripheral blood, for cancer screening.  
In this study we evaluated global DNA methylation status in laryngeal cancer tissues 
compared to normal laryngeal tissues and peripheral blood leukocytes in a homogeneous 
group of 72 patients with LSCC using a UPLC-based method (ultra performance liquid 
chromatography) to assess the total content of 5‘-methylcytosine.  
Among the 72 patients, aged from 43 to 86 (mean 59.19, standard deviation 7.99), 
were 64 men and 8 women. A survey of the patients was carried out regarding their age at 
onset, exposure to environmental carcinogens (alcohol, cigarettes, etc.), the type of treatment, 
duration of treatment from the time of diagnosis and family history. Each tumor was 
characterized in terms of clinical and pathological features. 
We found DNA hypomethylation both in tumor tissue and normal tissue (about 56% and 49% 
of tumor and normal tissues, respectively, were substantially hypomethylated. There was a 
highly significant correlation between the levels of 5‘-methylcytosine in these two types of 
tissue (p = 0.001, Spearman‘s test for correlation). The level of 5-methylcytosine in blood 
leukocytes was higher than in cancerous and normal tissues. A negative correlation was found 
between tumor grade and blood levels of 5-methylcytosine. 
The level of leukocyte DNA methylation measured using total 5-methylcytosine content 
cannot be used as a surrogate marker for genome methylation status in cancer tissues. Further 
studies are necessary to determine the correlation between the tumor grade and blood levels of 
5-methylcytosine. 
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 Abstract 2 (150 words) 
Background 
Global DNA hypomethylation is often determined in easily available tissue, such as 
peripheral blood. 
Methods 
We evaluated global DNA methylation status in cancer tissues compared to adjacent normal 
tissues and peripheral blood leukocytes in a homogeneous group of 72 patients with laryngeal 
cancer using a UPLC-based method (ultra performance liquid chromatography) to assess the 
total content of 5‘-methylcytosine. 
Results 
DNA hypomethylation was found in tumor tissue and normal tissue (56% and 49% of tumor 
and normal tissues, respectively, were substantially hypomethylated). There was a significant 
correlation between the levels of 5‘-methylcytosine in these two types of tissue (p = 0.001, 
Spearman‘s test for correlation). There was no significant DNA hypomethylation in blood 
leukocytes. A negative correlation between tumor grade and blood levels of 5-methylcytosine 
was found. 
Conclusion 
The level of leukocyte DNA methylation measured using total 5-methylcytosine content 
cannot be used as a surrogate marker for genome methylation status in laryngeal cancer 
tissues.  
 
Introduction 
Head and neck squamous cell carcinomas (HNSCCs) are a highly heterogenous group 
of cancers at the morphological, genetic and epigenetic levels [Crowe 2002, Demokan 2011, 
Martinez 2012]. One type of head and neck cancers is laryngeal cancer. The majority of such 
cases (95%) are diagnosed as laryngeal squamous cell carcinoma (LSCC)  [Wang 2011]. 
According to the European Cancer Observatory’s 2008 data for the European Union, 
laryngeal cancer ranks as the 13th most common malignancy in men and 21th most common 
malignancy in women [http://eu-cancer.iarc.fr; Marioni 2012].  
In Poland laryngeal cancer was in 9th place among all malignancies reported in 2009. 
In the years 1999-2009, from about 2100 to about 2700 new cases of laryngeal cancer were 
diagnosed annually [http://onkologia.org.pl]. Carcinogenesis in LSCC is a multifactorial 
process, in which both exposure to environmental factors and genetic/epigenetic changes play 
a role. Some interactions between two or more factors may have a multiplicative effect [Al-
Kayed 2006, Pelucchi 2011, Sinha 2012].   
One of the common epigenetic events observed in various types of human tumors is 
global DNA hypomethylation, which affects a variety of DNA sequences, including repetitive 
sequences (transposable elements interspersed throughout the genome, large repeat sequences 
and simple repeat ones), as well as single-copy genes (e.g. growth regulatory genes, tissue 
specific genes, developmentally critical genes) [Daura-Oller 2009, Das 2004, De Smet 2010, 
Ehrlich 2002, Hoffmann 2005, Poage 2011]. DNA hypomethylation may lead to 
chromosomal instability, loss of the imprinting (LOI) of specific genes, retrotransposition and 
oncogene activation [Das 2004, Daura-Oller 2009, De Smet 2010, Jintaridth 2010, McCabe 
2005, Pogribny 2010, Steinhoff 2002].  
To estimate levels of global DNA methylation, various methods determining the 
methylation of cytosine in the genome, such as assessment of the content of 5-methylcytosine 
or the methylation level in repetitive DNA sequences, can be used [Stach 2003, Weisenberger 
2005, Smith 2007, Yang 2004]. These repetitive elements, constituting about half of the 
human genome, are relatively rich in CpG dinucleotides (LINE - long interspersed nuclear 
element, mainly LINE-1, SINE - short interpresed nuclear element and Alu), and are used as 
surrogate markers for estimating genomic DNA methylation levels [Smith 2007, Yang 2004]. 
It is generally accepted that there is an association between global hypomethylation (the 5-
methylcytosine content) and hypomethylation of  repetitive sequences [Kaneda 2004, 
Weisenberger 2005], although some studies have found no such relation [Choi 2009].  
DNA hypomethylation in different cancers varies according to the type and stage of 
cancer [Furniss 2008, Hoffmann 2005]. In view of the positive association between tumor 
progression and metastasis, DNA hypomethylation may be a useful marker in classifying a 
cancer and predicting its clinical course [Hoffmann 2005].  
DNA hypomethylation is namely a reduction (usually by an average of 10%) in the 
level of methylation (5-methylcytosine content) in malignant tumors usually compared to 
adjacent normal tissue or analogous normal tissue from healthy controls [De Smet 2012, 
Ehrlich 2002, Taby 2010, Yang 2004, Zhu 2010]. However, due to the large heterogeneity of 
tissue, and invasiveness of the methods used, global DNA methylation is often evaluated in 
easily available tissue, such as peripheral blood, for epidemiological purposes and cancer 
screening [Choi 2009, Woo 2012, Zhu 2010]. Acoording to the meta-analysis done by Woo 
and Kim [Woo 2012], global DNA hypomethylation in peripheral leukocytes may be 
considered as a biomarker for cancer risk. However, the authors emphasize that this is 
dependent on the experimental methods and targeted region of DNA used to measure the 
global DNA hypomethylation level and cancer type. Several independent studies have found 
that global DNA hypomethylation in peripheral blood leukocytes may be a risk factor in 
cancer of the colon, breast, liver, bladder and some head and neck tumors [Cho 2010, Choi 
2009, Hsiung 2007, Moore 2008, Pufulete 2003, Wu 2012].  
Therefore, we evaluated global DNA methylation status in laryngeal cancer tissues 
compared to normal laryngeal tissues and peripheral blood leukocytes in a homogeneous 
group of patients with LSCC using a UPLC-based method (UPLC, ultra performance liquid 
chromatography) to assess the total content of 5‘-methylcytosine.  
 
Material 
Tissue samples used to analyze 5‘-methylcytosine levels were obtained from 72 
patients with LSCC (Table 1, 2). All the patients were Caucasians from the same region of 
Poland. Histopathologically confirmed laryngeal cancer tissue, adjacent normal laryngeal 
tissue (1.5-2 cm from the margin of the neoplastic lesion), and peripheral blood were 
collected from each patient. All tissue samples from the study group were taken during 
laryngectomy in the Department of Otolaryngology, Wroclaw Medical University, Poland and 
in the Department of Clinical Otolaryngology, 4th Military Hospital, Wroclaw, Poland. The 
clinical data were collected in these centers and in the Lower Silesian Oncology Center, 
Wroclaw, Poland.  
The study received approval from the Bioethics Committee of Wroclaw Medical University 
(KB-332/2006). 
 The mean age of the patients was 59.19 years with standard deviation 7.99 (range 43-
86 yrs). The median follow-up time was 29.4 months with standard deviation 27.7 months 
(range, 5 to 172 months). None of the patients had distant metastases at the moment of 
diagnosis. During follow-up, 7 patients were observed with distant metastases (9.7%), 19 
patients (26.4%) with recurrences of LSCC and 4 patients (2.8%) with secondary tumors.  A 
family history of cancer was found in 36% of LSCC patients (26 of 72). However, only 3 of 
these 26 cases related to head and neck tumors (2 carcinomas of the larynx, 1 cancer of the 
lower lip).  
 
Table 1. Clinical characteristics of the study group. 
Feature Number of cases (%) 
Laryngeal squamous cell carcinoma 
     keratinizing 
     nonkeratinizing 
Localisation 
     glottis 
     epiglottis 
     subglottis 
     transglottis 
Grade 
     G1 
     G2 
     G3 
Stage 
     I 
 
55 (76.39) 
17 (23.61) 
 
24 (33.33) 
8 (11.11) 
0 (0.00) 
40 (55.56) 
 
16 (22.22) 
45 (62.50) 
11 (15.28) 
 
3 (4.17) 
     II 
     III 
     IV 
Tumor size (T) 
     T1 
     T2 
     T3 
     T4 
     Tx 
Nodus metastasis (N) 
     N0 
     N1 
     N2 
     N3 
     Nx 
 
11 (15.28) 
29 (40.28) 
29 (40.28) 
 
3 (4.17) 
15 (20.83) 
30 (41.67) 
23 (31.94) 
1 (1.39) 
 
39 (54.17) 
7 (9.72) 
15 (20.83) 
2 (2.78) 
9 (12.50) 
 
Table 2. Demographic and lifestyle characteristics of the patients with laryngeal cancer. 
Feature Number of cases 
Smoking 
     smoking pack yrs. 
          ≤20 
         >20 
     time of smoking (yrs.) 
          <20  
          21-30 
          31-40 
          41-50 
          >51 
Alcohol consumption 
     no 
     occasionally 
     often 
     abuse 
Place of residence 
     village 
     small city 
     big city 
Education 
     primary 
     vocational 
     secondary 
     higher 
Negative environmental factors 
at work 
     yes 
     no 
 
71 (98.61%) 
9 (12.68%) 
62 (87.32%) 
 
9 (12.68%) 
32 (45.07%) 
20 (28.17%) 
10 (14.08%) 
1 (1.41%) 
 
4 (5.56%) 
9 (12.50%) 
32 (44.44%) 
27 (37.50%) 
 
21 (29.17%) 
34 (47.22%) 
17 (23.61%) 
 
22 (30.56%) 
34 (47.22%) 
12 (16.67%) 
4 (5.56%) 
 
 
36 (50.00%) 
36 (50.00%) 
 Methods 
Genomic DNA was isolated from fresh-frozen solid tissues using a Gentra Puregene Tissue 
Kit (QIAGEN) and from periferal blood leukocytes using a QIAamp DNA Blood Midi Kit 
(QIAGEN). UPLC was the method used to assess the total content of 5-methylcytosine (5mC) 
in the DNA of the studied tissues.  
Analysis procedure: 
I. DNA enzymatic hydrolysis to 2‘-deoxynucleosides (dN): dG (2‘-deoxyguanosine), dC (2‘-
deoxycytidine), dT (2‘-deoxythymidine), dA (2‘-deoxyadenosine), 5mdC (5-methyl-2‘-
deoxycytidine). 
1. 2 - 5μg DNA in a volume of 20μl was denaturated at 95oC for 10 minutes 
2. 50μl 30mM NaOAc (pH=5.2 Chempur), 3μl 20mM Zn2SO4  (Chempur) and 5μl 0.3 
U/μl  Nuclease P1 (Sigma Aldrich) were added to denaturated DNA. 
3. The mixture was incubated at 45oC for 30 minutes. 
4. 10 μl 1M TRIS (pH=8.0 Sigma Aldrich) and 3μl 1U/μl SAP (Shrimp Alkaline 
Phosphatase, Fermentas) were added to the mixture. 
5. The mixture was incubated at 37oC for 2h. 
II.  UPLC-based chromatographc separation using the ACQUITY Ultra Performance Liquid 
Chromatography™ system (Waters) with Tunable UV Detector.  
Separation of the five deoxynucleotides was performed using the ACQUITY UPLC 
BEH C18 Column, with a flow rate of 0.5ml/min. The mobile phase consisted of 50 mM 
KH2PO4 (Chempur) and 1.5% Metanol (Roche). The UV absorbance was monitored at 273 
nm.  
The standard solution consisted of 30mM from each dN: dA (2′-Deoxyadenosine 
monohydrate, Sigma-Aldrich), dG (2’-Deoxyguanosine, MP Biomedicals), dC (2′-
Deoxycytidine, Sigma-Aldrich), dT (Thymidine, Sigma-Aldrich) and 10mM - 5mdC (5-
Methyl-2'-deoxycytidine, TriLink BioTechnologies). 
All the data were processed using EMPOWER2 Software (Waters). 
The level of 5mdC (% of the dC level) present in DNA samples was calculated using the 
following equation [Coney 1997, Fuke 2004]: 
%5mdC=5mdC/(dC+5mdC) x 100 
Statistical analysis 
The Mann-Whitney test and Spearman and Kendall’s test for correlation were used 
(using the R and SPSS statistical packages).  
Results 
A clearly significant positive correlation between the frequency of methylation in 
cancer tissues and the frequency of methylation in normal tissues (i.e. individuals with a high 
frequency of methylation in normal tissues tend to have a high frequency of methylation in 
cancer tissues) was observed (p<0.001, Spearman’s test of correlation). The mean level of 
5mC in laryngeal cancer tissues and normal laryngeal tissues was similar, about 3.7% (Table 
3, Figure 1). We found tumor-to-tumor and normal tissue-to-normal tissue variability in the 
DNA methylation level (Table 3). According to previous studies by other authors,  the range 
of the global 5-methylcytosine content in human DNA samples from various normal tissues is 
from about 3.4 to 4.3% and a DNA sample is classified as substantially hypomethyleted if the 
global DNA methylation is ≤3.2% [Ehrlich 2002, Weisenberger 2005]. We found that about 
56% of cancer tissues and 49% of normal tissues were substantially hypomethylated , while 
Ehrlich found hypomethylation in about 35% of colon tumors and Smith et al. in about 67% 
of head and neck squamous cell cancers [Ehrlich 2002, Smith 2007]. 
The frequency of methylation in periferal blood leukocytes in our studies was higher 
than in both tumor and normal tissues (p<0.001, Wilcoxon signed rank test) (Table 3). The 
DNA methylation levels in peripheral blood leukocytes from patients with LSCC were higher 
than in normal leukocytes in the study by Ehrlich et al. (mean levels 5.6% and 3,9, 
respectively) [Ehrlich 2002]. Only 15.2% of the blood samples in our studies were 
hypomethyleted. 
We did not observe any correlations of the level of methylation in the examined 
tissues with the age of the patients, despite evidence that the level of global genomic 
demethylation is an age dependent process and differs according to the type of tissue [De 
Smet 2010, Fraga 2005, Fuke 2004, Suzuki 2006].  
 
Table 3. Levels of 5‘-methylcytosine in the studied tissues. 
Methylation 
  N 
Minimum 
(%) 
Maximum 
(%) Mean (%) 
Std. 
Deviation 
Cancer 72 0.012 (1.2) 0.113 (11.3) 0.03657 
(3.7) 
0.020855 
Normal 
tissue 
72 0.017 (1.7) 0.099 (9.9) 0.03711 
(3.7) 
0.016755 
Periferal 
blood 
leukocytes 
65* 0.020 (2.0) 0.144 (14.4) 0.05568 
(5.6) 
0.023790 
*seven DNA samples were degraded  
 
Figure 1. A typical image of the chromatographic separation of nucleotides after enzymatic 
DNA hydrolysis of cancerous tissue (authors' results). 
 
 
We did not observe any significant correlations between the 5mC level and the clinical data 
with the exception of the following: 
- a negative correlation between the tumor grade and levels of 5‘-methylcytosine in periferal 
blood leukocytes (p=0.018, Kendall’s correlation coefficient), and 
- a positive correlation between the frequency of alcohol consumption and the level of  5mC 
in the blood (p=0.032, Kendall’s correlation coefficient) was found. 
Discussion 
Changes in the level of genomic DNA methylation play an important role in many 
types of human malignancies during both  initiation and progression [De Smet 2010, Dong 
2003, Eden 2003, Hasegawa 2002, Pogribny 2010, Smiraglia 2003,]. The methylation status 
in such a heterogeneous group of neoplasms as head and neck cancers may vary according to 
many factors, such as clinical characteristics, e.g. anatomic location, environmental factors 
[Demokan 2011].  
We presented global DNA methylation based on assessing the total 5‘-methylcytosine 
content in a very homogenous group of HNSCC, in LSCC.  
 We found a significantly decreased level of DNA methylation in both types of 
laryngeal tissues, cancerous and normal. This is consistent with the observations of other 
authors, who described global DNA hypomethylation, e.g. in normal colon mucosa, colon 
adenomas and colon carcinomas or in other types of tumors and adjacent normal tissues [Choi 
2009, Cravo 1994, Figueiredo 2009, Poage 2011, Pufulete 2003]. Global hypomethylation in 
tumor tissues of head and neck tumors was also observed in LINE repetitive sequences by 
other authors, such as Smith et al. [Smith 2007]. The DNA methylation level of LINE-1 
elements in the study of Smith et al. was positively correlated with environmental factors, 
such as alcohol use and tobacco smoking, as well as high tumor stage [Smith 2007]. In our 
study we did not observe any correlation between DNA hypomethylation and the clinical 
data, such as disease stage, tumor size or recurrence, except for a negative correlation between 
the tumor grade and blood levels of 5-methylcytosine.  This suggests that DNA 
hypomethylation in peripheral blood leukocytes may be a marker for more aggressive tumors. 
Further studies are necessary to establish such a correlation, because the sample used had a 
prominent bias towards a specific grade (over 60% of samples were in G2). However, there 
are several reports of progressively increasing hypomethylation with increasing malignancy 
grade in a variety of tumors [Costello 2001, Zhu 2010]. 
The study performed by Szpakowski et al. using a genome-wide microarray approach 
to analyze squamous carcinomas of the head and neck showed disease-related alterations in 
DNA methylation [Szpakowski 2009]. This analysis suggested that in   tissues adjacent to the 
tumor there was generalized and highly variable disruption of epigenetic control across the 
repetitive DNA loci, while in tumor cells LINE-1 elements were preferentially demethylated. 
Recent studies of head and neck cancer by Poage et al. [Poage 2011] confirmed that global 
methylation is associated in a sequence-dependent manner. Also, Jackson et al. [Jackson 
2004] on the basis of their research consider that different types of cancers may vary in the 
timing and frequency of the DNA demethylation of specific repetitive sequences during 
tumorigenesis.  
The role of hypomethylation in carcinogenesis of LSCC is also confirmed by results 
from our previous studies. We found high level, statistically significant chromosomal 
rearrangements in centromeric and telomeric regions in LSCC in a CGH study [unpublished]. 
It has been shown that the demethylation of repetitive sequences located in centromeres, as 
well as regions around the centromeres or subtelomeric regions, can induce chromosomal 
instability [Narayan 1998, Martinez 2012, Pogribny 2010, Stach 2003], which play a role in 
HNSCC carcinogenesis [De Smet 2010, Eden 2003, Hermsen 1996, Jin 2000, Stembalska 
2002 - PhD thesis]. 
Taking into account the theory of field cancerization in HNSCC [Braakhuis 2003], we 
suggest that decreased DNA methylation levels in LSCC patients for cancerous and normal  
tissues may result from the impact of tobacco smoke [Smith 2007] and/or alcohol 
consumption (see Table 2) [Gabriel 2006, Pufulete 2005]. Current studies have shown that 
smoking and drinking alcohol are associated with low levels of vitamin B12, which is 
required for the synthesis of S-adenosylmethionine, SAM (a source of methyl groups in the 
methylation process) [Gabriel 2006, Pufulete et al. 2005, Smith 2007]. Also, 
microenvironmental hypoxia, which may be caused by smoking and alcohol consumption, can 
influence local epigenetic changes, leading to the inappropriate silencing and re-activation of 
genes involved in carcinogenesis [Fraga 2005, Shahrzad 2007]. Regions of solid tumors are 
temporarily and/or chronically exposed to hypoxia and reperfusion, which are known to 
contribute to the development of cancer [Shahrzad 2007]. Hypomethylation may also be 
related to a folate deficiency in one's diet [Figueiredo 2009, Pufulete 2003, Pufulete 2005, 
Sapkota 2008], or the presence of mutations or polymorphisms in genes encoding enzymes 
involved in folate and methionine (a precursor of SAM) metabolism, such as MTR 
(methionine synthase) or MTHFR (the 5,10-methylenetetrahydrofolate reductase), [Kruszyna 
2010, Paz 2002, Pufulete 2005]. The present study did not consider dietary and genetic 
factors, which could modify the results by influencing the metabolism of folic acid. Although 
it may be assumed that in our study group, which consisted almost entirely of smokers ( only 
one person did not smoke) and over 80% of whom were alcohol drinkers, there is a deficiency 
of various micronutrients in their diets. Piyathilake et al., who did not observe 
hypomethylation in oral squamous cell carcinomas in comparison to the results of earlier 
studies for squamous cell lung carcinomas using monoclonal antibodies specific to 5-
methylcytosine, suggested that various risk factors (including nutrition) and the activity of 
methyltransferases may affect the difference between hypomethylation levels in studied 
tumors [Piyathilake 2005].  
Except for a positive association between the frequency of alcohol consumption and 
the level of  5-methylcytosine in peripheral blood leukocytes, we did not find any effects of 
demographic or lifestyle factors on DNA methylation. An negative association was reported 
by Choi et al. However, the frequency of alcohol consumption did not affect the association 
between global DNA methylation and the risk of breast cancer [Choi 2009].  
 The methylation levels observed in our study in all tissues are similar to the specific 
kind of variation in methylation in head and neck cancers found by Poage et al. [Poage 2011]. 
The differences in methylation levels could indicate the coexistence of cells actually 
presenting hypermethylation. This observation is consistent with the results of other authors, 
such as Smith et al. [2007] and Ehrlich et al. [2002]. Further research is required to clarify the 
high level of methylation in peripheral blood leukocytes of LSCC patients. 
We did not find an association between DNA hypomethylation in tumor tissues and 
hypomethylation in peripheral blood leukocytes. Our results are similar to Furniss et al. 
[2008], who did not find any relationship between the level of methylation in tumor tissue and 
in blood for patients with laryngeal cancer. Therefore, we believe that peripheral leukocyte 
DNA methylation measured by 5-methylcytosine content cannot be used as a surrogate 
marker of genomic instability in LSCC.  
 
Conclusion: 
We found decreased global DNA methylation level in laryngeal cancer tissues and  
surrounding laryngeal tissue, indicating the presence of hypomethylation in both types of 
tissue. We suggest that hypomethylation in both tissues may be the result of field 
cancerization, but futher studies are needed to confirm this. Subsequent work will be 
necessary to investigate the negative correlation between the tumor grade and blood levels of 
5-methylcytosine found here. 
The level of leukocyte DNA methylation measured using total content of 5-methylcytosine 
cannot be used as a surrogate marker for genome methylation status in cancer tissues. 
 
Acknowledgements 
This work was supported by a Polish government grant for science  research projects 
(Contract No. 2360/B/P01/2008/34).  
The study was supported by a research fellowship within “The Development Program of 
Wroclaw Medical University” funded from the European Social Fund, Human Capital, 
National Cohesion Strategy” (contract no. UDA-POKL.04.01.01-00-010/08-01)”. 
References 
 
Al-Kayed S, Qasem MB: Laryngeal cancer. [Chapter 7 in: Freedman LS, Edwards BK, Ries 
LAG, Young JL (eds). Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, 
and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. 
National Cancer Institute, 2006. NIH Pub. No. 06-5873. Bethesda, MD]. 
http://mecc.cancer.gov/publication/mecc-monograph.pdf 
Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A Genetic 
Explanation of Slaughter’s Concept of Field Cancerization: Evidence and Clinical 
Implications. Cancer Res 2003; 63: 1727–1730. 
Cho YH, Yazici H, Wu H, Terry MB, Gonzalez K, Qu M, Dalay N, Santella RM. Aberrant 
promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues 
and blood from breast cancer patients. Anticancer Res 2010; 30: 2489–2496.  
Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, 
Karpf AR: Association between global DNA hypomethylation in leukocytes and risk of breast 
cancer. Carcinogenesis 2009; 11: 1889-1897. 
Coney CA, Wise CK, Poirier LA: An improved sample preparation method for the 
quantitative HPLC determination of 5-methyldeoxycytidine in animal tissue DNA. J Liq 
Chromatogr R T 1997; 8: 1279-1293. 
Costello JF, Plass C: Methylation matters. J Med Genet 2001; 38: 285-303. 
Cravo M, Fidalgo P, Pereira AD, Chaves P, Selhub J, Mason JB, Mira FC, Leitao CN: DNA 
methylation as an intermediate biomarker in colorectal cancer: modulation by folic acid 
supplementation. Eur J Cancer Prev 1994; 3: 473–9. 
Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H: Molecular pathology of head and neck 
cancer. Histol Histopathol 2002; 17: 909-914. 
Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-4642.  
Daura-Oller E, Cabre M, Montero MA, Paternain JL, Romeu A: Specific gene methylation 
and cancer: new insights into coding region features trends. Bioinformation 2009; 3: 340-343.  
Demokan S, Dalay N: Role of DNA methylation in head and neck cancer. Clin Epigenetics 
2011; 2:123-150. 
De Smet C, Loriot A: DNA hypomethylation in cancer. Epigenetic scars of a neoplastic 
journey. Epigenetics 2010; 5: 206-213. 
Dong SM, Sun DI, Benoit NE, Kuzmin I, lerman MI, Sidransky D: Epigenetic inactivation of 
RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9: 3635-3640. 
Eden A., Gaudet F, Waghmare A, Jaenisch R: Chromosomal Instability and Tumors 
Promoted by DNA Hypomethylation. Science 2003; 18: 455. 
Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 2002; 21: 
5400-5413. 
Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, Chen X, Bresalier RS, 
McKeown-Eyssen G, Haile RW, Baron JA, Issa JP: Global DNA methylation (LINE-1) in the 
normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol 
Biomark Prev 2009; 18: 1041-1049. 
Fraga M, Ballestar E, Pza M, Ropero S, Stien F, Ballestar M, Heine-Suner D, Cigudosa J, 
Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, 
Vaag A, Stephan Z, Spector T, Wu YZ, Plass C, Esteller M: Epigenetic differences arise 
during the lifetime of monozygotic twins. PNAS 2005; 30: 10604-10609. 
Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, Miyazaki T: Age related 
changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-
based study. Ann Hum Genet 2004; 68: 196-204. 
Furniss CS, Marsit CJ, Houseman EA, Eddy K, Kelsey KT: Line region hypomethylation is 
associated with lifestyle and differs by human papillomavirus status in head and neck 
squamous cell carcinomas. Cancer Epidemiol Biomark Prev 2008; 17: 966-971. 
Gabriel HE, Crott JW, Ghandour H, Dallal GE, Choi SW, Keyes MK, Jang H, Liu Z, Nadeau 
M, Johnston A, Mager D, Mason JB: Chronic cigarette smoking is associated with diminished 
folate status, altered folate from distribution, and increased genetic damage in the buccal 
mucosa of healthy adults. Am J Clin Nutr 2006; 83: 835-841. 
Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT: Patterns of gene 
promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002; 21: 
4231-4236. 
Hermsen MAJA, Joenje H, Arwert F, Welters MJP, Braakhuis BJM, Bagnay M, Westerveld 
A, Slater R: Centromeric breakage as a major cause of cytogenetic abnormalities in oral 
squamous cell carcinoma. Genes Chromosomes Cancer 1996; 15: 1-9. 
Hoffmann MJ, Schulz WA: Causes and consequences of DNA hypomethylation in human 
cancer. Biochem Cell Biol 2005; 83: 296-321.  
Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, Kelsey KT: 
Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell 
carcinoma. Cancer Epidemiol Biomark Prev 2007; 16: 108-114. 
http://eu-cancer.iarc.fr 
http://onkologia.org.pl 
Jin C, Jin Y, Wennerberg J, Dictor M, Mertens F: Nonrandom pattern of cytogenetic 
abnormalities in squamous cell carcinoma of the larynx. Genes Chromosomes Cancer 2000; 
28: 66-76. 
Jintaridth P, Mutirangura A: Distinctive patterns of age-dependent hypomethylation in 
interspersed repetitive sequences. Physiol Genomics 2010; 2: 194-200. 
Jackson K, Yu MC, Arakawa K, Fiala E, Youn B, Fiegl H, Müller-Holzner E, Widschwendter 
M, Ehrlich M. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer 
Biol Ther. 2004; 3:1225-12231.  
Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi M, Sugimura T, 
Tatematsu M, Ushijima T: Frequent hypomethylation in multiple promoter CpG islands is 
associated with global hypomethylation, but not with frequent promoter hypermethylation. 
Cancer Sci 2004; 1: 58-64. 
Kruszyna L, Lianeri M, Rydzanicz M, Gajecka M, Szyfter K, Jagodzinski PP: Polymorphic 
variants of folate metabolism genes and the risk of laryngeal cancer. Mol Biol Rep 2010; 37: 
241-247. 
Marioni G: Letter to the editors: Essentials for an updated epidemiology of laryngeal 
carcinoma. Cancer Treat Rev 2012; 38:559. 
Martinez JG, Pérez-Escuredo J, Castro-Santos P, Marcos CA, Pendás JL, Fraga MF, Hermsen 
MA: Hypomethylation of LINE-1, and not centromeric SAT-α, is associated with centromeric 
instability in head and neck squamous cell carcinoma. Cell Oncol (Dordr) 2012; 35: 259-267.  
McCabe DC, Caudill MA: DNA methylation, genomic silencing and links to nutrition and 
cancer. Nutr Rev 2005; 6: 183-195.  
Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, Garcia-Closas R, 
Chanock S, Tardon A, Serra C, Carrato A, Dosemeci M, Garcia-Closas M, Esteller M, Fraga 
M, Rothman N, Malats N: Genomic DNA hypomethylation as a biomarker for bladder cancer 
susceptibility in the spanish bladder cancer study: a case-control study. Lancet Oncol 2008; 9: 
359-366. 
Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Balin SB, Ehrlich M: Hypomethylation of 
pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77: 833-838. 
Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA, Sanchez-Cespedes M, 
Herman JG, Esteller M: Germ-line variants in methyl-group metabolism genes and 
susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 
2002; 62: 4519-4524. 
Pelucchi C, Tramacere I, Boffetta P, Negri E, La Vecchia C. Alcohol consumption and cancer 
risk. Nutr Cancer 2011; 63: 983-990. 
Piyathilake CJ, Bell WC, Jones J, Henao OL, Heimburger DC, Niveleau A, Grizzle WE: 
Pattern of nonspecific (or global) DNA methylation in oral carcinogenesis. Head Neck 2005; 
12: 1061-1067. 
Poage GM, Houseman EA, Christensen BC, Butler RA, Avissar-Whiting M, McClean MD, 
Waterboer T, Pawlita M, Marsit CJ, Kelsey KT: Global hypomethylation identifies loci 
targeted for hypermethylation in head and neck cancer. Clin Cancer Res 2011; 17: 3579-3589.  
Pogribny IP: Epigenetic events in tumorigenesis: putting the pieces together. Exp Oncol 2010; 
32: 132-136. 
Pufulete M, Al-Ghnaniem R, Khushal A, Appleby P, Harris N, Gout S, Emery PW, Sanders 
TAB: Effect of folic acid supplementation on genomic DNA methylation in patients with 
colorectal adenoma. Gut 2005; 54: 648–653. 
Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, Emery PW, Sanders 
TA: Folate status, genomic DNA hypomethylation and risk of colorectal adenoma and cancer: 
a case control study. Gastroenterology 2003; 124: 1240-1248. 
Sapkota A, Hsu CC, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Fabianova E, 
Rudnai P, Janout V, Holcatova I, Brennan P, Boffetta P, Hashibe M: Dietary risk factors for 
squamous cell carcinoma of the upper aerodigestive tract in central and eastern Europe. Canc 
Causes Contr 2008; 19: 1161-1170. 
Shahrzad S, Bertrand K, Minhas K, Coomber BL: Induction of DNA hypomethylation by 
tumor hypoxia. Epigenetics 2007; 2: 119-125. 
Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck 
cancer. Am J Otolaryngol 2012; 33: 130-136.  
Smiragilia DJ, Smith LT, Lang JC, Rush LJ. Dai Z, Schuller DE, Plass C: Differential targets 
of CpG island hypermethylation in primary and metastatic head and neck squamous cell 
carcinoma (HNSCC). J Med Genet 2003; 40: 25-33.  
Smith IM, Mydlarz WK, Mithani Sk, Califano JA: DNA global hypomethylation in squamous 
cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J 
Cancer 2007; 121: 1724-1728. 
Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Dohner H, Wiessler M, Lyko F: Capillary 
electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003; 31: e2. 
Steinhoff C, Schulz WA: Transcriptional regulation of the human LINE-1 retrotransposon 
L1.2B. Mol Genet Genomics 2003; 270: 394-402. 
Stembalska A: Badania nad utratą heterozygotyczności wybranych genów oraz 
niestabilnością genetyczną w plaskonabłonkowym raku krtani [PhD thesis, in Polish]. 
Wrocław, 2002.  
Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M: Global 
DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic 
damage. Cancer Cell 2006; 9: 199-207. 
Szpakowski S, Sun X, Lage JM, Dyer A, Rubinstein J, Kowalski D, Sasaki C, Costa J, Lizardi 
PM. Loss of epigenetic silencing in tumors preferentially affects primate-specific 
retroelements. Gene 2009; 448: 151-167. 
Taby R, Issa JPJ: Cancer epigenetics. Ca Cancer J Clin 2010; 60: 376-392. 
Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN. The involvement of CHD5 
hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol 2011; 47: 601-608.  
Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, 
Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW. CpG island methylator 
phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF 
mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.  
Woo HD, Kim J: Global DNA hypomethylation in peripheral blood leukocytes as a biomarker 
for cancer risk: a meta-analysis. PLoS One 2012; 7:e34615. 
Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM: Global DNA methylation levels 
in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control 
study. Carcinogenesis. 2012; 33: 1340-1345.  
Yang AS, Estécio MRH, Doshi K, Kondo Y, Tajara EH, Issa JPJ: A simple method for 
estimating global DNA methylation using bisulphate PCR of repetitive DNA elements. 
Nucleic Acids Res 2004; 32: e38. 
Zhu  ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, Litonjua AA, Zanobetti A, Vokonas P, 
Wright RO, Baccarelli A, Schwartz J: Repetitive element hypomethylation in blood leukocyte 
DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative 
Aging Study. Cancer Causes Control 2011; 22: 437-447. 
 
